A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice - Institut Pasteur Access content directly
Journal Articles Frontiers in Immunology Year : 2022

A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice

Abstract

Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. Here we report a messenger RNA vaccine directly encoding for a nanoparticle displaying 60 receptor binding domains (RBDs) of SARS-CoV-2 that acts as a highly effective antigen. A construct encoding the RBD of the Delta variant elicits robust neutralizing antibody response, and also provides protective immunity against the Delta variant in a widely used transgenic mouse model. We ultimately find that the proposed mRNA RBD nanoparticle-based vaccine provides a flexible platform for rapid development and will likely be of great value in combatting current and future SARS-CoV-2 variants of concern.
Fichier principal
Vignette du fichier
Brandys-2022-A mRNA Vaccine Encoding for a RBD.pdf (6.37 Mo) Télécharger le fichier
Origin : Publication funded by an institution
Licence : CC BY - Attribution

Dates and versions

pasteur-03854887 , version 1 (16-11-2022)

Licence

Attribution

Identifiers

Cite

Pascal Brandys, Xavier Montagutelli, Irena Merenkova, Güliz T Barut, Volker Thiel, et al.. A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice. Frontiers in Immunology, 2022, 13, pp.912898. ⟨10.3389/fimmu.2022.912898⟩. ⟨pasteur-03854887⟩

Collections

PASTEUR
19 View
32 Download

Altmetric

Share

Gmail Facebook X LinkedIn More